Bayerische Motoren Werke ADR (BMWYY)

The Scottsdale-based specialist marks its order milestone alongside a growing aftermarket range, with recent additions including carbon fiber hoods and tunes.

Scientists have been struggling to understand why more people who are less than 55 years of age are being diagnosed with cancer. These cases are described as early-onset cancer because cancers typically tend to develop in people above 55, but this is changing and researchers want to know why .

Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, announced it will host a live webinar Sept. 23 at 12:30 p.m. Eastern to present the business model, development roadmap and value proposition of Open-Medicine AI (“OMAI”), its wholly owned subsidiary developing a multi-agentic AI platform for end-to-end therapeutic development. The session, led by Panna Sharma, founder and CEO of Open-Medicine AI, will cover OMAI platform architecture, expansion beyond rare cancers into additional disease categories and therapeutic modalities and its planned subscription and enterprise licensing business model.

ERIE, Pa. — September 16, 2026 — When actor Ryan Reynolds wanted a custom motorcycle for an annual long-distance ride with his brother, he turned to Boxr Moto, an Erie, Pennsylvania-based custom BMW motorcycle builder founded by Joshua Snider.

Earth Science Tech (OTC: ETST) recently reported Q1 2027 results that management says demonstrate continued progress from its strategy of acquiring and scaling profitable healthcare, pharmaceutical, and telemedicine businesses. For the quarter ended June 30, 2026, revenue rose 3% to $9.0 million, gross profit increased 3.1% to $6.3 million, net income climbed 57% to $715,697, operating cash flow more than doubled to $707,131, and total assets grew 33.3% to $10.4 million compared with Q1 2026. Looking ahead, ETST plans to expand geographically, develop its telehealth and pharmacy fulfillment platforms, improve operating efficiency, and pursue greater institutional investor participation.

September 15, 2026 - Atlanta Metro Law is addressing the legal challenges facing motorcycle riders injured in left-turn and intersection collisions, following a fatal crash in southeast Atlanta and ahead...

For decades, lots of American patients have been traveling to “fringe” countries like Turkey, Cuba and Thailand in search of affordable, quality healthcare due to the persistent challenges plaguing the American health care system. Now the latest destination of choice for cancer treatment is China, according to a report by the WSJ (Wall Street Journal).

ATLANTA, GA - September 14, 2026 - Atlanta Accident Lawyers is addressing the legal challenges facing motorcycle crash victims after three fatal motorcycle collisions were reported in the Atlanta area...

When visiting a modern and sophisticated city like Dubai with your partner, you should look for a two-door car with beautiful lines and an excellent perfor

BMW 5 Series Rental Dubai, Sheer Driving ExperienceFor sheer driving experience, the BMW 5 series is the ultimate solution in Dubai. To navigate the mighty

A Frankfurt-listed group trading since 1912 holds 4.4 on Trustpilot and a B+ BBB grade

As more Americans become underinsured or uninsured as a result of rising health insurance premiums and the several changes that were passed in the Big Beautiful Act, the impacts of the rising numbers of the uninsured are likely to be felt by every American . Several healthcare professionals have sounded the alarm on this brewing issue.

A knee that once carried a runner through marathons or a hiker up a steep mountainside can be sidelined by a single defect in cartilage. More broadly, nearly a half-million Americans end up with knee cartilage damage each year as a result of long-term wear and tear and every-day accidents. For decades, many available treatments have focused on managing pain and restoring functions rather than actually replacing damaged cartilage with healthy tissue. Regentis Biomaterials (NYSE American: RGNT) is pursuing a different approach with GelrinC, an off-the-shelf hydrogel implant designed to support the regeneration of cartilage within the damaged area.

A foreign language can open up valuable career possibilities, especially when it is connected to a strong economy and an international job market. Among th

A 4.4 Trustpilot score sits beside a 1.9 BBB customer review average in the September 2026 files

MARIETTA, GA – September 10, 2026 Humanity has learned to live and work in space. Artificial intelligence has transformed daily life. Technology has advanced far beyond what once seemed possible.

BioMedWire Editorial Coverage: Today’s multiple sclerosis treatments can slow down disease progression, but none of them halt it outright, and none give back the function patients have already lost. Close to a million people in the United States, and nearly 2.9 million worldwide, live with that reality, watching a condition that steadily chips away at mobility, eyesight and basic physical control. That gap in treatment options just picked up a serious new contender. Quantum BioPharma Ltd. (NASDAQ: QNTM) ( Profile ) has received U.S. Food and Drug Administration (“FDA”) clearance to launch a phase 2 trial of Lucid-MS, a patented, first-in-class candidate designed not to calm the immune system but to shield, and potentially rebuild, the myelin sheath itself. The clearance sets up what would be the first time in history that a drug built on this exact mechanism gets tested in people living with MS, a milestone significant enough that it has already drawn a fresh buy rating from Wall Street analysts. That momentum puts Quantum BioPharma squarely among a group of leading pharma companies, including Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX) and Bristol-Myers Squibb Company (NYSE: BMY), that are focused on treating serious diseases and areas of major…

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.

Earth Science Tech (OTC: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, began the current fiscal year 2027 in a position of real financial strength, according to CEO and Board Chairman Giorgio R. Saumat letter to shareholders ( https://ibn.fm/NC6CW ). This position is the result of meaningful progress over the last several years, which built a business that is not only durable, self-sustaining, and positioned for long-term growth but also anchored in a conglomerate model, infrastructure as a service, and end-to-end vertical integration.

For many women, UTIs are something they routinely experience. These usually start as a burning sensation or a sudden urge to use the bathroom. For some, there is a sudden onset of discomfort that they just cannot ignore. While many receive a dose of antibiotics after being told what’s bothering them “is just a UTI,” several questions remain in the mind of the woman .

Nutriband (NASDAQ: NTRB) announced that CEO Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on Sept. 16, 2026, at Nasdaq MarketSite in New York. The summit will bring together biotechnology executives, investors and industry leaders for an evening of thought leadership and networking.

BMW of Cincinnati North has added 2027 BMW X7 models to its new-vehicle inventory, giving Cincinnati-area drivers access to BMW's three-row luxury SUV with available configurations including the X7 xDrive40i and X7 M60i.

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost. Nearly one million people in the United States, and close to 2.9 million worldwide, live with that reality, watching a disease that can gradually erode mobility, vision, and basic bodily control. That gap has just gotten a serious new challenger. Quantum BioPharma Ltd. (NASDAQ: QNTM) ( Profile ) has received FDA clearance to begin a phase 2 trial of Lucid-MS, a patented, first-in-class drug candidate aimed not at calming the immune system but at protecting and potentially repairing the myelin sheath itself. The clearance sets the stage for what would be the first time in history that a drug candidate built on this specific mechanism is tested in people living with the MS disease, a milestone significant enough that it has already drawn a fresh buy rating from Wall Street analysts. This momentum places Quantum BioPharma solidly in a group of leading companies focused on the treatment of serious diseases and areas of significant unmet medical need across vaccines, ophthalmology and neurological disease, including Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and…

Your wedding day is filled with special moments, and transportation is an important part of making those moments comfortable, stylish, and stress-free. Fro

Motorcycle winter storage in Toronto means secure storage, proper maintenance, battery care, and a bike that is serviced, protected, and ready to ride come spri